Financial Survey: Candel Therapeutics (NASDAQ:CADL) versus NKGen Biotech (NYSE:NKGN)

Risk and Volatility

Candel Therapeutics has a beta of -0.88, meaning that its stock price is 188% less volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Valuation & Earnings

This table compares Candel Therapeutics and NKGen Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120,000.00	1,146.86	-$37.94 million	($1.69)	-2.54
NKGen Biotech	$80,000.00	106.09	-$82.94 million	($5.08)	-0.05

Candel Therapeutics has higher revenue and earnings than NKGen Biotech. Candel Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Candel Therapeutics and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-629.29%	-134.23%
NKGen Biotech	N/A	N/A	-479.36%

Institutional & Insider Ownership

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by insiders. Comparatively, 74.7% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.